And now…finally…some good news in dry AMD! Geographic atrophy (GA) remains a significant unmet need that has been met with great attention by investigators and industry. However, until now, all…

Genentech reported yesterday that lampalizumab did not meet the primary endpoint in SPECTRI, one of the two parallel Phase III clinical trials investigating lampalizumab injections for the treatment of geographic…

In June, Novartis announced results from HAWK and HARRIER, two phase III clinical trials comparing brolocizumab (formerly RTH258) to aflibercept for the treatment of wet AMD. The primary endpoints were…